Doctor Strange dominates the US box office

Cumberbatch as Doctor Strange

by James White |
Published on

Following a typically strong Marvel opening here in the UK and other countries, Doctor Strange swept into US cinemas and landed an impressive $84.9 million in its first weekend, according to studio estimates.

Combined with its overseas earning, the film – which sees Benedict Cumberbatch's arrogant surgeon Stephen Strange learning to channel the mystic arts – has earned more than $325.3 million at the box office. The movie's US opening was roughly comparable to Guardians Of The Galaxy and marks another success for the company.

Its closest competitor for the weekend was DreamWorks Animation's Trolls, which made $45.6 million. Third was Mel Gibson's new war film Hacksaw Ridge, which overcame its violent nature and R-rating to score $14.7 million.

Tyler Perry's Boo! A Madea Halloween finally lost its spot at the top after two weeks spent sitting there, as business had been expected to drop off after the Halloween season passed. Still, the movie added $7.8 million for a $64.9 million total so far. In fifth we find Inferno, which is bringing in lacklustre numbers compared to the other Dan Brown adaptations from Ron Howard and Tom Hanks. The third in the series made $6.2 million this week, and is up to $26 million in the States, though its international figures are healthier and the movie stands at $185.3 million worldwide.

The Accountant added $5.9 million for sixth, while Jack Reacher: Never Go Back fell from third to seventh on $5.5 million. Horror sequel Ouija: Origin Of Evil conjured up $3.9 million, while The Girl On The Train slipped three places to ninth with $2.7 million. Finally, Miss Peregrine's Home For Peculiar Children dropped a few places itself, landing 10th thanks to $2.1 million. Tim Burton's latest has so far earned $83.3 million in the States.

Benedict Cumberbatch talks Doctor Strange.

Just so you know, whilst we may receive a commission or other compensation from the links on this website, we never allow this to influence product selections - read why you should trust us